Riskpilot← Back to searchSign inGet full accessARCORAL PHARMA AS
ASActiveOrg 996673898Reistadlia 32, 3425 ReistadResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20110 employees
Revenue 2024
NOK 0
EBITDA margin
—
-403% vs 2023
Equity ratio
90.9%
Financial strength
Net profit 2024
NOK -70K
-402% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -90K | -403% |
| Net profit | NOK -70K | -402% |
| Total assets | NOK 310K | -24% |
| Equity | NOK 282K | -20% |
| Employees | 0 | — |
Legal name
ARCORAL PHARMA AS
Org number
996673898
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
10. mars 2011
Share capital
NOK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Daglig leder alene.
Company purpose
Utvikling, lisensiering og salg av famasøytiske produktrettigheter og produkter hva hermed står i forbindelse, samt investering i andre selskaper.
Address
Reistadlia 32, 3425 Reistad
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 2 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −786 | −18 | −12 | −18 | −90 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −786 | −18 | −12 | −18 | −90 |
| Net financials | −68 | −0 | −0 | −0 | 0 |
| Profit before tax | −854 | −18 | −12 | −18 | −90 |
| Tax | −188 | −4 | −3 | −4 | −20 |
| Net profit | −666 | −14 | −9 | −14 | −70 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 722 | 464 | 437 | 406 | 310 |
| Equity | 390 | 375 | 366 | 352 | 282 |
| Long-term debt | 91 | 73 | 58 | 46 | 27 |
| Short-term debt | 1 242 | 16 | 13 | 8 | 2 |
| Total debt | 1 333 | 89 | 71 | 54 | 28 |
EBITDA margin
-9010800.0%
This company
15.8%
Market median
-57030480% vs market
20202024
Equity ratio
90.9%
This company
38.2%
Market median
+138% vs market
20202024
Return on equity
-24.9%
This company
18.4%
Market median
-235% vs market
20202024
Net profit margin
-7019600.0%
This company
8.1%
Market median
-86661828% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.10×
This company
0.62×
Market median
+84% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
VJ Chief Executive Officer | Chief Executive Officer | 2015 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2017 | |
| Board of Directors | 2017 | |
| Board of Directors | 2017 | |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Marnic As
ARCORAL PHARMA AS Board members of ARCORAL PHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Vibeke Johansen | Chief Executive Officer | 0 companies |
| Bjørn Tormod Johansen | Chairman | 0 companies |
| Christian Fredrik Johansen | Board of Directors | 0 companies |
| Rolf Hilmar Nicolaissen | Board of Directors | 0 companies |